Medicofarma Biotech SA
WSE:MDB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.377
1.225
|
| Price Target |
|
We'll email you a reminder when the closing price reaches PLN.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Medicofarma Biotech SA
Cost of Revenue
Medicofarma Biotech SA
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Medicofarma Biotech SA
WSE:MDB
|
Cost of Revenue
-zł259.4k
|
CAGR 3-Years
55%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
I
|
Inno-Gene SA
WSE:IGN
|
Cost of Revenue
-zł666k
|
CAGR 3-Years
51%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
13%
|
|
|
R
|
Ryvu Therapeutics SA
WSE:RVU
|
Cost of Revenue
-zł22.7m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
14%
|
CAGR 10-Years
-6%
|
|
|
S
|
Selvita SA
WSE:SLV
|
Cost of Revenue
-zł70.1m
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Medicofarma Biotech SA
Glance View
Medicofarma Biotech SA is a biotechnology company, which focuses on the innovative medicine, medicinal products, and biotechnology products. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2008-11-27. The company is engaged in works on drugs, medical devices and biotechnological products. It's research and development works are carried out in laboratories in Lublin and Poznan.
See Also
What is Medicofarma Biotech SA's Cost of Revenue?
Cost of Revenue
-259.4k
PLN
Based on the financial report for Dec 31, 2023, Medicofarma Biotech SA's Cost of Revenue amounts to -259.4k PLN.
What is Medicofarma Biotech SA's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
41%
Over the last year, the Cost of Revenue growth was 92%. The average annual Cost of Revenue growth rates for Medicofarma Biotech SA have been 55% over the past three years , 41% over the past five years .
You don't have any saved screeners yet
